Cancer Genetics and Epigenetics 2018, Vol.6, No.2, 13-18
17
References
Badowskakozakiewicz A.M., and Budzik M.P., 2016, Immunohistochemical characteristics of basal-like breast cancer, Contemporary Oncology, 20(6): 436
Bakha E.E.A., EI-Sayed M.E., and Green A.R., 2007, Prognostic markers in triple-negative breast cancer, Cancer, 109(1): 25-32
PMid:17146782
Banerji S., Cibulskis K., Rangel-Escareno C., et al, 2012, Sequence analysis of mutations and translocations across breast cancer subtypes, Nature, 486(7403):
405-4
PMid:22722202 PMCid:PMC4148686
Chaudhuri Q.G., and Misra S., 2016, Abstract 4587: Dynactin dysregulation-induced increase in EGFR on basal-like breastcancer cells, Cancer Research,
76(14): 4587-4587
Cynthia B., Ahmed S., Michel G., et al., 2017, DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is
synergistic with anti-CTLA-4 immunotherapy, AnticaMed Oncol, Dec 18, 35(1):13
Dai H., Roman C., Alicia Y., et al., 2016, PIM kinase inhibition presents a novel targeted therapy against triple-negative breast tumors with elevated MYC
expression, Nat Med, Nov, 22(11): 1321-1329
PMid:27775705 PMCid:PMC5341692
Dang Q.H., Cao J., Zhang H.H., et al., 2018, Clinicopathological characteristics and immunohistochemical indexes in patients with Sanyin Breast Cancer,
Journal of Applied Cancer, 33(10): 1693-1703
Fara B.M., Simone F., Steven C., et al., 2016, PIM1 kinase regulates cell death, tumor growth and chemotherapy response revealing a novel target in
triple-negative breast cancer, Nat Med, Nov, 22(11): 1303-1313
PMid:27775704 PMCid:PMC5552044
Grobmyer S.R., and Djohan R., 2017, Comments on “Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing
mastectomy” by Cont et al. Breast, Breast Cancer Res Treat, 166(1): 323-3
PMid:28744750
Gucalp A., Tolaney S., Isakoff S.J., et al., 2013, Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic
breast cancer, Clin Cancer Res, 19(19): 5505-5512
PMid:23965901 PMCid:PMC4086643
Ho-Yen C.M., Green A.R., Rakha E.A., et al., 2014, C-Met in invasive breast cancer, is there a relationship with the basal-like subtype, Cancer, 120(2): 163-71
PMid:24150964
Hoadley K.A., Hoadley M.B., Kanchi K.L., et al., 2016, Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of
multiple metastases, Plos Medicine, 14(1): e1002174
PMid:27923045 PMCid:PMC5140046
Ishitha G., Manipadam M.T., Backianathan S., et al., 2016, Clinicopathological study of triple negative breast cancers, Journal of Clinical and Diagnostic
Research, 10(9): EC05-9
Jung E.C., Su H. K., Soo J. L., and Young K. B., 2015, Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer,
Surgical Oncology, 22: 82-89
PMid:25145503
Katz H., and Alsharedi M., 2018, Immunotherapy in triple-negative breast cancer, Drugs, Sep, 29(8): 774-785
Lehmann B.D., Bauer J.A., Chen X., et al., 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted
therapies [J], J Clin Invest, 121(7): 2750-2767
PMid:21633166 PMCid:PMC3127435
McNamara K.M., Yoda T., Nurani A.M., et al., 2014, Androgenic pathways inthe progression of triple-negativebreast carcinoma: a comparison between
aggressive and non-aggressive subtypes, Breast Cancer Res Treat, 145(2): 281-293
PMid:24715382
